Medicus Pharma advances pipeline during Q2 with key milestones

Medicus Pharma (NASDAQ:MDCX) has reported 2nd 4th fiscal results and regulatory and objective advancement crossed its SkinJect and Teverelix programs, portion raising astir $40 cardinal done equity and indebtedness financing during the archetypal fractional of 2026.

The institution said it received FDA "Study May Proceed" authorization for its registrational SkinJect survey successful patients with Gorlin Syndrome.

Its Teverelix programme received Institutional Review Board authorization and affirmative FDA feedback for an optimized Phase 2 survey successful acute urinary retention, portion the institution besides received UAE Department of Health authorization to statesman the PRECISION-E2 Phase 2 survey evaluating Teverelix successful women with symptomatic endometriosis.

"The 2nd 4th of 2026 marked a defining play for Medicus arsenic we successfully precocious some of our pb therapeutic platforms into their adjacent stages of objective and regulatory development, portion strengthening our equilibrium expanse and fiscal flexibility," Medicus CEO Dr. Raza Bokhari said.

"We judge Medicus is good positioned with 2 differentiated programs advancing towards late-stage development, each addressing important commercialized opportunities done chiseled regulatory pathways and aggregate anticipated value-creating milestones."

For SkinJect, Medicus reported further pre-specified analyses from its completed Phase 2 SKNJCT-003 study, showing objective and histological clearance rates of 64% and 55%, respectively, astatine the 200 microgram dose. The institution said the FDA authorization allows it to initiate the registrational SKNJCT-005 survey successful Gorlin Syndrome and that it continued moving with the Gorlin Syndrome Alliance and objective investigators connected the improvement program.

The institution said the developments enactment its planned FDA 505(b)(2) regulatory strategy for SkinJect.

For Teverelix, Medicus said it received IRB authorization and affirmative FDA feedback for an optimized Phase 2 survey focused connected preventing relapse of acute urinary retention. The institution besides received UAE authorization for the PRECISION-E2 study, which volition usage genomics to measure Teverelix successful women with symptomatic endometriosis.

Medicus besides appointed Dr. Faisal Mehmud, CEO of its Antev Limited subsidiary, arsenic an further relation alongside his presumption arsenic the company's main aesculapian officer.

Financially, Medicus reported cash, currency equivalents and restricted currency of $25.2 cardinal arsenic of June 30, including $15.2 cardinal successful currency and currency equivalents, compared with $9.7 cardinal a twelvemonth earlier.